

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.com

Tata Power and NIEPID unveil Phygital Neurodiversity Platform

29 April 2024 | News

Aimed at supporting individuals with neurodiversity issues, particularly children with autism



Tata Power Community Development Trust (TPCDT) has partnered with Tata Elxsi, a global leader in design and technology services, to drive their "Pay Attention" initiative forward. Leveraging Tata Elxsi's innovative digital therapeutics (DTx) solution, TEcare, TPCDT aims to accelerate the development of the India Neurodiversity Platform.

This phygital platform is the result of a collaborative effort between Tata Power Community Development Trust (TPCDT) and the National Institute for the Empowerment of Persons with Intellectual Disabilities (NIEPID) and is aimed at supporting individuals with neurodiversity issues, particularly children with autism. It will revolutionise neurodiversity screening, diagnosis, disease management, and care for individuals with special needs.

TEcare, developed by Tata Elxsi, serves as a foundational platform for hosting and integrating various disease-specific DTx modules. With its unified data repository, TEcare simplifies the process of preventing, diagnosing, treating, and managing patients' medical conditions holistically.

Not only does it accelerate healthcare solutions with its built-in features, but it also provides healthcare professionals with access to a wealth of patient data points, enhancing their decision-making capabilities.

Explaining Tata Power's philosophy, Himat Tewari, CHRO, and Chief - CSR & Sustainability said, "Recognising the significant impact of Autism Spectrum Disorder, affecting 1 in 100 children, the Pay Attention initiative addresses the critical need for a comprehensive support network. The India Neurodiversity Platform signifies a substantial advancement in efforts to narrow access disparities and cultivate supportive environments for everyone."

The first phase, the neurodiversity platform is expected to onboard around 5,000 users and is directed towards Tier II and Tier III cities with few care providers for neurodiversity with the help of screening and early diagnosis for early intervention. In the current phase, this platform can be accessed on a tab or a computer. A wider rollout on smartphones is expected in upcoming phases.